Cagrilintide Dosage Guide, Benefits & Side Effects

As of 2026, Cagrilintide itself is investigational and not approved by the FDA or other regulators for human use; it exists in the research pipeline primarily through registered Phase III clinical trials conducted under an Investigational New Drug (IND) framework. The combination product CagriSema (cagrilintide plus semaglutide) has been submitted to the FDA for review, with a decision anticipated later in 2026, but as of now it is not an approved prescription medication. Material sold outside of clinical trials is typically labeled 'for research use only, not for human consumption,' and using it outside of a supervised clinical trial carries legal and safety risks.

In research contexts, Cagrilintide is typically supplied as a lyophilized (freeze-dried) powder, which is its most stable form. Unopened lyophilized vials are generally reported to remain stable for 18-24 months when kept refrigerated (2-8°C), or longer at -20°C for extended storage, and should be protected from light. Suppliers commonly reconstitute with sterile (bacteriostatic or plain sterile) water rather than saline, since the peptide dissolves readily without added salts. Once reconstituted, the solution is generally recommended to be kept refrigerated and used within about 28 days. These are general handling practices reported by peptide suppliers and are not medical instructions, since Cagrilintide is not approved for human administration outside clinical trials.

As with other potent weight-loss agents (including GLP-1 drugs), a portion of weight lost during cagrilintide or CagriSema treatment in trials has included lean mass alongside fat mass, which is a common concern raised in discussions of this drug class. Researchers and clinicians studying these compounds have noted this as an area of ongoing investigation, and some trials have looked at resistance training or combination therapies to help preserve lean mass during treatment. This remains a topic of active research rather than a settled finding specific to Cagrilintide alone.

No. Cagrilintide is a distinct molecule (an amylin analog) with a different mechanism than GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) or the dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound). It is not interchangeable with these drugs and is not itself an approved medication; most of the clinical interest in Cagrilintide comes from its use in combination with semaglutide (as CagriSema) rather than as a standalone approved therapy.